Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Senti Biosciences Holdings, Inc.

NASDAQ: SNTI · Life Sciences · 6 alerts · CIK 1854270

Share price
$0.1360Close, Nov 16
Market cap
$11.7M
Shares outstanding
85.71MLatest SEC cover page
Sector
Life Sciences
Industry
Biological Products, (No Diagnostic Substances)SIC 2836

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Senti Biosciences Holdings, Inc. filings on SEC EDGAR ↗

4:37 PM ET 8-K
Capital Raise

Senti Biosciences Holdings Capital Raise

Senti Biosciences entered into an equity commitment letter with CPIF II-9 Limited, an affiliate of Celadon Partners, for the purchase of up to $4.55 million of common stock. The commitment is structured to be funded in quarterly tranches through December 31, 2027, at a price per share based on Nasdaq's Minimum Price definition. The company also agreed to provide the investor with customary demand and piggyback registration rights for the shares issued.

Counterparty
CPIF II-9 Limited
Term
through Dec 2027
4:38 PM ET 8-K
M&A Deal

Senti Biosciences Holdings M&A Deal with ST NewCo Limited

Senti Biosciences announced a record date of October 30, 2026, for the distribution of contingent value rights (CVRs) related to its merger with ST NewCo Limited, which closed on October 21, 2026. Additionally, board member Edward Mathers resigned from the Board of Directors and all associated committees effective October 27, 2026.

Counterparty
ST NewCo Limited
4:17 PM ET 8-K
Divestiture

Senti Biosciences Holdings Divestiture to ST NewCo Limited for $60M

Senti Biosciences completed the divestiture of its entire ownership interest in its operating subsidiaries, Midco and Opco, to ST NewCo Limited. In exchange, Senti shareholders will receive contingent value rights (CVRs) entitling them to up to $60.0 million in milestone payments tied to the FDA approval and commercial success of the CAR-NK cell therapy SENTI-202.

Value
$60M
Counterparty
ST NewCo Limited
Term
7 years
4:02 PM ET 8-K
Shareholder Meeting

Senti Biosciences Holdings Shareholder Meeting

Senti Biosciences held its reconvened 2026 Annual Meeting of Stockholders where shareholders elected three Class I directors and ratified KPMG LLP as the independent auditor. Crucially, stockholders approved the Merger Agreement with ST NewCo Limited and authorized a reverse stock split at a ratio between 1-for-20 and 1-for-50.

4:01 PM ET 8-K
Shareholder Meeting

Senti Biosciences Holdings Shareholder Meeting

Senti Biosciences Holdings, Inc. convened its 2026 Annual Meeting of Stockholders on October 8, 2026, but adjourned the meeting without conducting any business. The adjournment was intended to provide additional time to solicit stockholder votes in favor of a Merger Agreement Proposal. The meeting is scheduled to reconvene on October 15, 2026.

4:04 PM ET 8-K
Leadership Change

Senti Biosciences Holdings Leadership Change

Brenda Cooperstone, Ph.D., resigned from the Board of Directors and as Chair of the Compensation Committee, effective September 23, 2026. The company stated her departure was not due to any disagreement regarding operations, policies, or practices.

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.